Hypoactive sexual desire disorder (HSDD) affects approximately 10% of premenopausal women and is significantly undertreated — partly because patients hesitate to raise it, partly because physicians are undertrained, and partly because until recently treatment options were extremely limited. There are now two FDA-approved pharmacological treatments: flibanserin (Addyi®) and bremelanotide (Vyleesi®), plus compounded PT-141 troches. Understanding the differences between them matters clinically.
What Is PT-141 / Bremelanotide?
Bremelanotide (brand name Vyleesi®) is a melanocortin receptor agonist — specifically MC3R and MC4R in the CNS. These receptors are involved in sexual motivation and desire pathways. Unlike estrogen or testosterone, bremelanotide is entirely non-hormonal — it works through neurotransmitter pathways, not the endocrine system. PT-141 is the research designation; in clinical practice it refers to both FDA-approved Vyleesi® and compounded bremelanotide formulations.
Phase 3 Evidence: RECONNECT Trials
FDA approval was based on two Phase 3 RECONNECT trials involving 1,267 premenopausal women with HSDD. Primary endpoints: FSFI desire domain and FSSD-DAO (distress scale).
- Statistically significant improvement in sexual desire vs placebo across both trials — ~25–35% more bremelanotide patients reported meaningful improvement
- Statistically significant reduction in distress — both symptoms improved, which is clinically important because the diagnosis requires distress
- Responder rate: ~25% of bremelanotide patients reported "much improved" or "very much improved" global sexual function vs ~17% on placebo — a real but moderate treatment effect
- No improvement in arousal or orgasm — bremelanotide specifically targets desire; not indicated for primary arousal or orgasmic dysfunction
FDA-Approved Vyleesi® vs Compounded PT-141 Troches
| Feature | Vyleesi® (FDA-approved) | Compounded PT-141 Troche |
|---|---|---|
| Route | Subcutaneous autoinjector | Sublingual (dissolves under tongue) |
| Dose | 1.75 mg; max 1/24h, 8/month | 1–2 mg; 1–2h before activity |
| Onset | ~45 min; 6–8h duration | ~1–2h; lower bioavailability |
| Cost | ~$290–350/dose cash | ~$99–129/30-count (Valiant, MediVera) |
| Regulatory | FDA-approved, known PK | Off-label; not bioequivalent to Vyleesi® |
PT-141 vs Addyi® (Flibanserin)
- Addyi®: Daily bedtime pill — not on-demand. Significant alcohol interaction (severe hypotension risk; alcohol must be avoided within 2h, ideally avoided during treatment). Mechanism: serotonin/dopamine pathways. ~$149/month through specialty pharmacies. Best for patients who prefer daily oral therapy and can avoid alcohol.
- PT-141/Vyleesi®: On-demand injection or troche 45–120 min before activity. No alcohol restriction. Best for situational treatment or patients who cannot consistently avoid alcohol.
No head-to-head trial has compared the two. Your physician will discuss which fits your clinical situation and preferences.
Side Effects and Contraindications
- Nausea: Most common (~40% in trials); transient (1–2h post-dose). Significantly reduced on empty stomach or with prophylactic anti-nausea medication.
- Flushing: ~20%; transient warmth/redness
- Headache: ~11%; usually mild
- Transient BP elevation: Mean SBP +2 mmHg / DBP +1 mmHg lasting ~12h. Larger in a small subset.
Contraindications: Uncontrolled hypertension (absolute); established CVD (physician evaluates risk-benefit); pregnancy (animal teratogenicity data — reliable contraception required); severe hepatic impairment.
Telehealth Scope for Women's Sexual Health
YourMD can evaluate and prescribe for HSDD via telehealth for premenopausal women with straightforward presentations. Referral required for: sexual dysfunction primarily from physical causes (vulvodynia, vaginismus, pelvic floor dysfunction — gynecology/pelvic floor PT); significant relationship contributors (sex therapy); complex menopausal HRT interactions (gynecology co-management).
Related: Sublingual vs Oral Sildenafil (Men's Health) · Why We Research More Than We Prescribe